The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.

from #Infections via alexandrossfakianakis on Inoreader http://ift.tt/1lfXEM1
via IFTTT

from #Med Blogs by Alexandros G.Sfakianakis via paythelady61 on Inoreader http://ift.tt/1QGqmTt
via IFTTT